Adaptimmune Therapeutics Plc (NASDAQ: ADAP)
Adaptimmune Therapeutics Plc Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Adaptimmune Therapeutics Plc Company Info
Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the provision and development of novel cell therapies and novel cancer immunotherapy products to people with cancer. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
News & Analysis
Why Shares of Adaptimmune Therapeutics Jumped Tuesday
The company bulks up its pipeline by regaining the rights to two of its clinical programs.
Why Adaptimmune Therapeutics Stock Is Glowing Green Today
Positive trial data is powering the biotech's stock higher today.
Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket
Here's why these Fool.com contributors bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.
Why Adaptimmune Therapeutics Stock Is Popping Today
Buyout fever is sparking interest in the biotech's beaten-down shares today.
Why Shares of Adaptimmune Therapeutics Rose 13.4% on Tuesday
The clinical-stage biotech saw its shares rise after releasing preclinical data on two of its therapies.
Why Adaptimmune Therapeutics, Agenus, and Sorrento Therapeutics Popped Today
Regeneron's buyout of Checkpoint Pharmaceuticals is sparking a rally among clinical-stage cancer companies today.
Why Adaptimmune Therapeutics Shares Dropped 14.7% on Monday
Investors were not pleased that the company is preparing for a stock sale.
2 Cancer Stocks With Absurdly Low Valuations
The biotech bear market has punished these two stocks too severely at this point.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.